- Connecticut AG William Tong, together with a bipartisan coalition of AGs from 23 states and the District of Columbia, filed amicus curiae briefs in two appellate cases before the Third Circuit and the District of Columbia Circuit.
- In the briefs, the coalition defended the actions of the U.S. Department of Health and Human Services in cases brought by pharmaceutical giants Sanofi-Aventis U.S., Novo Nordisk, Novartis Pharmaceuticals, and United Therapeutics Corp. The pharmaceutical companies have challenged violation orders issued by HHS for their noncompliance or adoption of one-sided restrictions on the distribution of affordable drugs under the 340B Drug Pricing Program, which requires discounted drug pricing for institutions serving low-income or underserved patient populations.
- In the briefs, the amici states claim that the pharmaceutical companies have limited the ability of safety-net healthcare providers to use retail community pharmacies to dispense affordable prescription drugs, and in effect are refusing to offer these providers discounted prices on critical prescription drugs. This threatens the interests of the amici states because the safety-net providers are unable to provide vulnerable patients with affordable prescription drugs as required by the 340B Program.